Mostrar el registro sencillo del ítem
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
dc.contributor.author | Isla, D. | |
dc.contributor.author | Massuti, B. | |
dc.contributor.author | Lazaro Quintela, Martín | |
dc.contributor.author | de Alda, L. R. | |
dc.contributor.author | Gordo, R. | |
dc.contributor.author | Ortega-Joaquín, N. | |
dc.contributor.author | Oyagüez, I. | |
dc.date.accessioned | 2022-05-24T12:13:17Z | |
dc.date.available | 2022-05-24T12:13:17Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1758-1966 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32256712 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16817 | |
dc.description.abstract | Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. Methods: Management cost/year (euro 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively). Results: Management cost was euro6173.42/patient-year without BM and euro21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (euro4948.51/patient-year). Conclusion: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC. | en |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib | en |
dc.type | Journal Article | es |
dc.authorsophos | Isla, D.;Massuti, B.;Lázaro, M.;de Alda, L. R.;Gordo, R.;Ortega-Joaquín, N.;Oyagüez, I. | |
dc.identifier.doi | 10.2217/lmt-2019-0011 | |
dc.identifier.pmid | 32256712 | |
dc.identifier.sophos | 41280 | |
dc.issue.number | 1 | es |
dc.journal.title | Lung Cancer Manag | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médica | es |
dc.page.initial | Lmt28 | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | CHUVI | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 9 | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International
![](/xmlui/themes/Mirage2//images/final_lines.png)